Pharmaceutical Business Review reports, Bafna Pharmaceuticals, a Chennai, India-based contract research manufacturer, plans to buy Raricap from Johnson & Johnson for INR210m. Raricap, which contains calcium, folic acid and iron, is used to treat anaemia in pregnant women. Bafna Pharma intends to sell the anemia drug globally, Reuters reported citing two sources with direct knowledge of the deal. Reportedly, once the deal is concluded, Johnson & Johnson will lose rights over the Raricap trademark and the product. Bafna Pharma manufactured Raricap for Johnson & Johnson for a few years, however it stopped the arrangement after the drug went through certain formulation changes.